Spotlight Asset Group’s Sarepta Therapeutics SRPT Stock Holding History

Spotlight Asset Group’s Portfolio SRPT Stock Details SRPT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q3	$92K	Hold	10,000	–	–	0.05%	113
2021 Q2	$60K	Hold	10,000	–	–	0.02%	127
2021 Q1	$78K	Sell	10,000 -10,000	-50%	-$923K	0.03%	128
2020 Q4	$44K	Hold	20,000	–	–	0.02%	135
2020 Q3	$15K	Buy	+20,000	New	+$3.04M	0.01%	148
2020 Q2	–	Sell	-10,000	Closed	-$112K	–	151
2020 Q1	$112K	Hold	10,000	–	–	0.06%	109
2019 Q4	$160K	Buy	+10,000	New	+$1.01M	0.08%	120

Other funds holding SRPT

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return

ACA

Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

FCM

Farallon Capital Management San Francisco, California $17.5B AUM 50.95% 1-Year Est. Return

Bank of New York Mellon New York $544B AUM 28.31% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

Spotlight Asset Group's SRPT Position: Q2 2024 in Review

Spotlight Asset Group held its Sarepta Therapeutics (SRPT) position steady in Q2 2024 at 700 shares worth $111K. The position accounts for 0.08% of the portfolio, ranked #100.

Spotlight Asset Group first reported a position in SRPT in Q4 2019 and has held it in 12 quarters since. The position peaked at $620K in Q4 2019. 484 funds tracked by Wall St. Rank hold SRPT as of Q2 2024.

Spotlight Asset Group held 700 shares of Sarepta Therapeutics worth $111K as of Q2 2024.
Spotlight Asset Group left its Sarepta Therapeutics share count unchanged in Q2 2024.
Sarepta Therapeutics made up 0.08% of Spotlight Asset Group's portfolio in Q2 2024, its #100 holding.
Spotlight Asset Group first reported a position in Sarepta Therapeutics in Q4 2019 and has held it in 12 quarters since.
Spotlight Asset Group's Sarepta Therapeutics position peaked at $620K in Q4 2019.
484 funds tracked by Wall St. Rank held Sarepta Therapeutics as of Q2 2024.

Based on Spotlight Asset Group's 13F filing for Q2 2024, filed 24 Jul 2024.